Company intelligence / Profile preview

Linno Pharmaceuticals

Shanghai, Shanghai, Chinalinnopharma.com ↗

Ownership: Private
Development stage: Other

Overview

Linno Pharmaceuticals has developed proprietary platforms enabling long half-life biologics and efficient blood-brain barrier penetration. Its lead programs include a recombinant arylsulfatase A enzyme for MLD with orphan drug designation from the FDA, as well as several antibody/nanobody-based therapeutics targeting rare neurological and immune diseases. Most programs are in preclinical or early clinical stages; no late-stage or commercialized products reported as of May 2025.

Therapeutic areas: OncologyOphthalmologyNephrologyNeurology
Modalities: AntibodiesNanobodiesRecombinant proteinsEnzymesAntibody fusion proteins
Industry: Biotech

Drug pipeline

17 assets

SLN12140

16 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Linno Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Linno Pharmaceuticals.

Explore the full profile